Stockreport

BioAtla out-licenses BA3362 to Context Therapeutics [Seeking Alpha]

BioAtla, Inc.  (BCAB) 
PDF Under the deal, BioAtla will receive $15M in upfront and near-term milestone payments. It will also be eligible to receive to up to $118.5M in various milestone payment [Read more]